Solid Lipid Oral Formulations for Controlled Release of Lipophilic Drugs
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing oral formulations of lipophilic drugs, particularly cannabinoids, suffer from poor solubility, enzymatic degradation, and lack of controlled release, leading to low bioavailability and stability issues.
Innovation Solution
Development of solid compositions comprising lipophilic actives, lipids, surfactants, and amphiphilic solvents, which form nanoparticles upon contact with aqueous media, providing controlled release and improved bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If lipophilic actives are formulated in traditional solid oral formulations, then manufacturing is simplified, but solubility and bioavailability remain poor
Solution Approach 1:
The patent changes the physical-chemical parameters of the lipophilic active by incorporating it into a lipid matrix formulation. This transforms the drug from a poorly soluble crystalline state to a solubilized state within the lipid vehicle, dramatically improving its apparent solubility and bioavailability while maintaining solid dosage form manufacturability
Solution Approach 2:
The patent creates a composite material system consisting of the lipophilic active embedded within a lipid matrix containing multiple components (lipids, surfactants, co-solvents). This composite structure provides both the manufacturability of solid formulations and the solubility enhancement of liquid lipid formulations
2Reliability
If liquid formulations are used to improve solubility, then bioavailability increases, but stability decreases due to solvent evaporation and interaction with capsule materials
Solution Approach 1:
The patent utilizes phase transition by designing a lipid matrix that is liquid at gastrointestinal tract temperatures (enabling drug solubilization and absorption) but solid or semi-solid at storage temperatures (providing formulation stability). This temperature-dependent phase behavior resolves the contradiction between solubility and stability
Solution Approach 2:
The patent replaces expensive soft gelatin capsules with more stable alternative delivery systems such as hard gelatin capsules, sachets, or direct oral administration of the lipid formulation, eliminating the stability issues associated with soft gelatin while maintaining liquid lipid benefits
3Ease of operation
If soft gelatin capsules are used for liquid formulations, then administration is simplified, but shelf life is limited and batch variability increases
Solution Approach 1:
The patent replaces soft gelatin capsules with alternative delivery systems including hard gelatin capsules, sachets containing the lipid formulation, or direct oral administration. These alternatives provide equal or superior shelf life and reduced batch-to-batch variability while maintaining ease of administration
4Reliability
If lipophilic actives are dispersed in aqueous media, then absorption is enhanced, but enzymatic degradation increases due to first and second pass metabolism
Solution Approach 1:
The patent uses the lipid matrix as an intermediary carrier that solubilizes the lipophilic active and facilitates its transport through the gastrointestinal tract. The lipid vehicle protects the drug from enzymatic degradation by maintaining it in a solubilized, less accessible state while enhancing its absorption through the GI mucosa
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compositions exhibit enhanced solubility, stability, and bioavailability, with controlled release capabilities, suitable for various administration forms and industries.
Implementation Method 1
when contacting or dissolving the compositions in an aqueous medium (e.g., oral or gastric fluids or moisture of the skin), the compositions spontaneously form drug containing nanoparticles
Implementation Method 2
the compositions are highly homogenous as solids, with no evidence of crystallization, yet they easily reach a complete dissolution or dispersion in an aqueous milieu
Implementation Method 3
a liquid crystal forming mixture of a surfactant and a lipid
Implementation Method 4
exhibiting a characteristic single endotherm by differential scanning calorimetry, suggesting homogeneity, no crystallization or sedimentation and a complete dissolution of the incorporated active
Implementation Method 5
liquid pro-nano-lipid formulations (LPNFs) of lipophilic drugs can be adsorbed onto particles of a porous inorganic polymer to form solid formulations
Data Source
AI summary
The invention includes improved pharmaceutical formulations of lipophilic actives, and specifically solid and semi-solid forms and oral dosage forms of such formulations that exhibit improved properties of controlled or modifiable release of actives and actives bioavailability upon dissolution in aqueous conditions at body temperature.